

Mark J Niciu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5082552/publications.pdf>

Version: 2024-02-01

71
papers

4,491
citations

87723

38
h-index

106150

65
g-index

75
all docs

75
docs citations

75
times ranked

5971
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutamate-based preclinical and clinical dysfunction and treatment in bipolar disorder. , 2022, , 215-252.		0
2	Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology. <i>Chronic Stress</i> , 2021, 5, 247054702110142.	1.7	15
3	Subanesthetic Dose of Ketamine Increases Mitochondrial Respiration in Human Neurons. <i>Biological Psychiatry</i> , 2020, 87, S340-S341.	0.7	0
4	Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder. <i>Chronic Stress</i> , 2019, 3, 247054701986526.	1.7	6
5	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 243-246.	0.7	3
6	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. <i>Psychopharmacology</i> , 2018, 235, 1923-1932.	1.5	162
7	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 232, 310-315.	2.0	87
8	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. <i>Journal of Affective Disorders</i> , 2018, 231, 51-57.	2.0	62
9	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. <i>Molecular Psychiatry</i> , 2018, 23, 1626-1631.	4.1	48
10	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. <i>EJNMMI Research</i> , 2018, 8, 57.	1.1	144
11	Characterizing the course of suicidal ideation response to ketamine. <i>Journal of Affective Disorders</i> , 2018, 241, 86-93.	2.0	44
12	Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. <i>Current Neuropharmacology</i> , 2017, 15, 57-70.	1.4	78
13	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , 2017, 81, 886-897.	0.7	334
14	The role of adipokines in the rapid antidepressant effects of ketamine. <i>Molecular Psychiatry</i> , 2017, 22, 127-133.	4.1	75
15	1004. Clinical Predictors of an Antisuicidal Response to Ketamine. <i>Biological Psychiatry</i> , 2017, 81, S406.	0.7	1
16	296. Correlating Peripheral and Central Markers of Neuroinflammation to PET Imaging of Translocator Protein (TSPO). <i>Biological Psychiatry</i> , 2017, 81, S122.	0.7	0
17	1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression. <i>Biological Psychiatry</i> , 2017, 81, S405-S406.	0.7	0
18	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. <i>Journal of Affective Disorders</i> , 2017, 218, 195-200.	2.0	94

#	ARTICLE	IF	CITATIONS
19	199. Associations between Specific Dissociative Symptoms and Symptom Subsets and Anti-Depressant Response to Ketamine. <i>Biological Psychiatry</i> , 2017, 81, S82-S83.	0.7	0
20	330. A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression. <i>Biological Psychiatry</i> , 2017, 81, S135.	0.7	2
21	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2017, 31, 1570-1577.	2.0	17
22	Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. <i>Journal of Affective Disorders</i> , 2017, 208, 560-566.	2.0	53
23	cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. <i>Molecular Psychiatry</i> , 2017, 22, 754-759.	4.1	81
24	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1068-1074.	1.1	55
25	Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 825-831.	1.1	53
26	A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. <i>Psychopharmacology</i> , 2016, 233, 1119-1130.	1.5	59
27	Reliability of ^1H -MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 88-98.	1.9	35
28	Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. <i>Neural Plasticity</i> , 2015, 2015, 1-7.	1.0	17
29	Ketamine for depression: evidence, challenges and promise. <i>World Psychiatry</i> , 2015, 14, 348-350.	4.8	49
30	Ketamine's Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	33
31	Novel Glutamatergic Treatments for Severe Mood Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 198-208.	0.6	29
32	A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. <i>Bipolar Disorders</i> , 2015, 17, 438-443.	1.1	88
33	Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. <i>Journal of Psychiatric Research</i> , 2015, 68, 68-73.	1.5	54
34	Anticonvulsants for the Treatment of Alcohol Withdrawal Syndrome and Alcohol Use Disorders. <i>CNS Drugs</i> , 2015, 29, 293-311.	2.7	51
35	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 97-114.	1.1	169
36	Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. <i>Acta Neuropsychiatrica</i> , 2015, 27, 143-152.	1.0	28

#	ARTICLE	IF	CITATIONS
37	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , 2015, 29, 596-607.	2.0	175
38	A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 187, 241-244.	2.0	9
39	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. <i>Journal of Affective Disorders</i> , 2015, 172, 307-311.	2.0	27
40	Biomarkers in mood disorders research: developing new and improved therapeutics. <i>Revista De Psiquiatria Clinica</i> , 2014, 41, 131-134.	0.6	11
41	Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine. <i>Pharmacopsychiatry</i> , 2014, 47, 141-144.	1.7	14
42	Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 298-307.	4.0	53
43	In Vivo Evidence for $\alpha 2$ Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared With Nonsmokers With Schizophrenia. <i>Biological Psychiatry</i> , 2014, 76, 495-502.	0.7	41
44	Do the dissociative side effects of ketamine mediate its antidepressant effects?. <i>Journal of Affective Disorders</i> , 2014, 159, 56-61.	2.0	227
45	Neuroimaging in Alcohol and Drug Dependence. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 45-54.	0.6	22
46	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. <i>Depression and Anxiety</i> , 2014, 31, 297-307.	2.0	43
47	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. <i>Journal of Neural Transmission</i> , 2014, 121, 907-924.	1.4	115
48	Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 119-139.	4.2	140
49	Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 2-16.	1.3	26
50	Riluzole likely lacks antidepressant efficacy in ketamine non-responders. <i>Journal of Psychiatric Research</i> , 2014, 58, 197-199.	1.5	20
51	Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. <i>Journal of Psychiatric Research</i> , 2014, 58, 161-166.	1.5	224
52	Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. <i>Molecular Psychiatry</i> , 2014, 19, 962-964.	4.1	27
53	Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e417-e423.	1.1	120
54	Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e932-e938.	1.1	84

#	ARTICLE	IF	CITATIONS
55	Pharmacologic Treatment of Dimensional Anxious Depression. primary care companion for CNS disorders, The, 2014, 16, .	0.2	32
56	Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior. , 2014, , 209-221.		0
57	Neurobiological aspects of suicide and suicide attempts in bipolar disorder. Translational Neuroscience, 2013, 4, 203-216.	0.7	34
58	Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine. Biological Psychiatry, 2013, 73, e37-e38.	0.7	17
59	Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders. CNS Drugs, 2013, 27, 777-787.	2.7	51
60	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectrums, 2013, 18, 231-241.	0.7	39
61	NEUROBIOLOGY OF ANXIOUS DEPRESSION: A REVIEW. Depression and Anxiety, 2013, 30, 374-385.	2.0	96
62	Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 74, e23-e24.	0.7	33
63	Defining anxious depression: a review of the literature. CNS Spectrums, 2013, 18, 252-260.	0.7	83
64	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. CNS Spectrums, 2013, 18, 242-251.	0.7	15
65	Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. Journal of Psychopharmacology, 2013, 27, 651-654.	2.0	40
66	NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16720-16725.	3.3	226
67	Overview of glutamatergic neurotransmission in the nervous system. Pharmacology Biochemistry and Behavior, 2012, 100, 656-664.	1.3	224
68	Subtypes of major depression in substance dependence. Addiction, 2009, 104, 1700-1709.	1.7	20
69	Altered ATP7A expression and other compensatory responses in a murine model of Menkes disease. Neurobiology of Disease, 2007, 27, 278-291.	2.1	67
70	Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience, 2006, 139, 947-964.	1.1	72
71	A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni. FASEB Journal, 2004, 18, 114-121.	0.2	36